GlassScriptPhysician profile
Ibrahim T Aldoss
NPI 1861692485
$175,267.66
in general payments reported to CMS, 2019-2025
29 companies · $72K in 2025
The $72K reported for 2025 was more than what 97% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,150 · 2020: $11K · 2021: $14K · 2022: $11K · 2023: $15K · 2024: $43K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $93K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $14K · Food and Beverage: $3,229 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $92,666.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,885.83 |
| Travel and Lodging | $14,124.34 |
| Food and Beverage | $3,229.06 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $679.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $47,631.38 | 2020-2025 | Rylaze |
| Kite Pharma, INC. | $28,322.74 | 2019-2025 | Yescarta, Tecartus |
| Amgen INC. | $24,868.45 | 2020-2025 | Blincyto, Evenity, Blincyto |
| Astrazeneca Pharmaceuticals LP | $13,006.97 | 2023-2025 | |
| Pfizer INC. | $12,770.07 | 2021-2024 | |
| Syndax Pharmaceuticals, INC. | $11,214.45 | 2025 | Revuforj |
| Takeda Pharmaceuticals U.S.A., INC. | $8,700.46 | 2021-2024 | Iclusig |
| Servier Pharmaceuticals LLC | $7,650.00 | 2024 | |
| Autolus INC | $5,182.33 | 2025 | |
| Astrazeneca Uk Limited | $4,920.00 | 2025 | |
| Abbvie INC. | $2,899.18 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $2,545.75 | 2024 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $2,478.06 | 2025 | |
| Agios Pharmaceuticals, INC. | $2,200.00 | 2021 | |
| Taiho Oncology, INC. | $308.18 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $126.12 | 2021-2024 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $110.27 | 2020-2024 | Ultomiris |
| Stemline Therapeutics INC. | $97.40 | 2025 | Orserdu |
| Genmab U.S., INC. | $53.42 | 2023-2024 | Epkinly |
| Merck Sharp & Dohme LLC | $39.12 | 2023-2024 | Dificid, Prevymis |
| Genentech USA, INC. | $29.91 | 2024 | Polivy |
| Pharmacyclics LLC, An Abbvie Company | $25.40 | 2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $24.30 | 2021 | |
| Genzyme Corporation | $23.68 | 2023 | |
| Astellas Pharma US INC | $22.20 | 2025 | Vyloy |
| Seagen INC. | $17.82 | 2023 | Adcetris |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Aldoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.